So far, more than 500 different pathogenic mutations in endoglin have been reported, concerning up to 59% of the HHT patient population, thus defined as the HHT1 subtype [9]. This evidence concerns the gene ENG and telangiectasia, hereditary hemorrhagic, type 1.